PositiveID Corporation Enters Into Strategic Financings for Up to $13.8 Million at a Premium to Current Share Price

PositiveID Corporation ("PositiveID" or "Company") PSID -13.16% , a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that it has entered into a series of agreements for investment commitments with Ironridge Global Technology and its affiliates ("Ironridge"), under which Ironridge has committed, subject to certain conditions, to purchase common and preferred stock totaling up to $13.8 million in several transactions. Two of the transactions include a purchase of perpetual, redeemable, premium fixed priced convertible preferred stock. The preferred stock is convertible into shares of the Company's common stock at a minimum conversion price of $0.50, which represents a premium of 32 percent over the closing price on July 27, 2011. Future tranches of the transactions will include conversion pricing based on the market price of the common stock at the time of the tranche, subject to a minimum conversion price of $0.50. Consistent with its company policy, Ironridge has represented that it has never shorted PositiveID stock and is contractually prohibited from future short sales for one year. If the total amount of the financings is completed, PositiveID believes that it will have funding through at least 2012, including the continued development of its diabetes management products and biological detection technologies. 

Palomar Medical Reports Financial Results For Second Quarter 2011

Palomar Medical Technologies, Inc. PMTI +0.49% , a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the second quarter ended June 30, 2011. Revenues for the quarter ended June 30, 2011 were $16.3 million, a 4 percent increase over the $15.6 million reported in the second quarter of 2010. Product revenues increased to $10.1 million, a 9 percent increase over the $9.2 million reported in the second quarter of 2010. Second quarter gross margin from product revenues was 61 percent, as compared to 62 percent reported in the second quarter of 2010. Net loss for the second quarter ended June 30, 2011 was $4.0 million, or $0.21 per share, which included $1.2 million in patent litigation expense and $1.0 million in non-cash stock-based compensation expense. Net loss for the second quarter ended June 30, 2010 was $1.7 million, or $0.09 per share, which included $0.7 million in patent litigation expense and $1.0 million in non-cash stock-based compensation expense. The balance sheet continues to be strong with $91.1 million in cash, cash equivalents, short-term investments, and marketable securities and other investments with no borrowings. 

Boston Scientific Profits Up, Beat Expectations

Spurred by sales of medical devices beyond its core cardiovascular business, Boston Scientific Corp. said Thursday that profit rose in the second quarter.

The Natick, Mass.-based medical technology company, which employs about 5,000 people in Minnesota, said sales in the quarter ended June 30 were essentially flat at $2 billion.

Net income for the quarter was $146 million, or 10 cents a share, compared with $98 million, or 6 cents a share, the same period a year ago.

Wall Street was expecting earnings of 9 cents a share.

Taking into account $116 million in various charges, adjusted net income for the quarter was $262 million, or 17 cents a share, versus $190 million, or 12 cents a share.

Aggravations Associated with Hiatal Hernia and Acid Reflux Disorder Can Be Cured by Natural Means

We are living in a community where medical troubles seem to be a part of everyday life. In order to be healthy and strong for your family, you need to be conscious of certain diseases along with their warning signs. Understanding the warning signs of widespread medical conditions makes it possible to get medical help before the issue gets more serious. So before you decide on a treatment it is a good idea to understand your hiatal hernia symptoms. The abdomen is supposed to stay inside the abdominal cavity. Hiatal hernia arises when a section of the stomach projects through an opening into the chest cavity. The esophagus travels down from a tiny opening in the diaphragm and on to the abdominal cavity, which is where it makes way for the stomach. Often, because of certain medical conditions, a part of the stomach makes its way up that very small hole in the diaphragm and lodges itself into the chest cavity. This condition is called hiatal hernia. Most of the people, who have this particular problem, don't get any sort of symptoms at all, nevertheless for others the scenario is a bit different. Probably the most typical problems for hiatal hernia are acid reflux, nausea, heart problems and irregular bowel movements. 

Aspirin Cancer Connection is Promising

A new study has found that taking low-dose aspirin could reduce risk of cancer. This study has been published within the Lancet. The research, published today, reviewed eight previous studies involving 25,500 subjects. There are still major spaces in this research. You shouldn't immediately start taking aspirin, however talk with your doctor. 

Aspirin may be able to cease cancer

British researchers were on a team that did the meta-study published. They found that 75 milligrams of aspirin taken regular for five years or more reduces the risk of dying from cancer. There was a 20 percent decrease in dying from lung and prostate cancer, a 54 percent decrease in gastrointestinal cancers and a 60 percent decrease in esophageal cancers. There were daily low-dose aspirin taken by individuals. Between 5 and 20 years was how long each did it. The research was not about cancer originally. It was about the effect that taking regular aspirin has on cardiovascular effect. 

Terahertz Light Illuminates For Inexpensive Cancer Cell Biology Research

Unique research carried out at the Science and Technology Facilities Council's (STFC) Daresbury Laboratory in Cheshire is set to trigger a new era in research into cancer diagnosis and our understanding of how living things function.

Scientists from the University of Liverpool are linking up to Europe's most intense terahertz light source at Daresbury's ALICE accelerator, with its state-of-the-art tissue culture centre and beamline to understand the effects of terahertz (THz) rays on human cells. This improved understanding of human cells could eventually lead to significant advances in human development and the understanding of diseases, including melanomas and esophageal cancer.